دورية أكاديمية
أعرض في EDS

Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue-specific drug binding, transport, and metabolism.

التفاصيل البيبلوغرافية
العنوان: Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue-specific drug binding, transport, and metabolism.
المؤلفون: Witta S; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.; School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado, USA., Collins KP; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.; School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado, USA., Ramirez DA; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA., Mannheimer JD; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.; School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado, USA., Wittenburg LA; Department of Surgical and Radiological Sciences, University of California, Davis, California, USA.; University of California, Davis Comprehensive Cancer Center, Sacramento, California, USA., Gustafson DL; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.; School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado, USA.; Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, Colorado, USA.; Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA.
المصدر: Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Feb; Vol. 11 (1), pp. e01052.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Hoboken, NJ] : John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics, [2013]-
مواضيع طبية MeSH: Vinblastine*/pharmacokinetics , Antineoplastic Agents*/pharmacokinetics, Humans ; Dogs ; Mice ; Animals ; Cytochrome P-450 CYP3A/genetics ; Drug Interactions ; Biological Transport
مستخلص: Vinblastine (VBL) is a vinca alkaloid-class cytotoxic chemotherapeutic that causes microtubule disruption and is typically used to treat hematologic malignancies. VBL is characterized by a narrow therapeutic index, with key dose-limiting toxicities being myelosuppression and neurotoxicity. Pharmacokinetics (PK) of VBL is primarily driven by ABCB1-mediated efflux and CYP3A4 metabolism, creating potential for drug-drug interaction. To characterize sources of variability in VBL PK, we developed a physiologically based pharmacokinetic (PBPK) model in Mdr1a/b(-/-) knockout and wild-type mice by incorporating key drivers of PK, including ABCB1 efflux, CYP3A4 metabolism, and tissue-specific tubulin binding, and scaled this model to accurately simulate VBL PK in humans and pet dogs. To investigate the capability of the model to capture interindividual variability in clinical data, virtual populations of humans and pet dogs were generated through Monte Carlo simulation of physiologic and biochemical parameters and compared to the clinical PK data. This model provides a foundation for predictive modeling of VBL PK. The base PBPK model can be further improved with supplemental experimental data identifying drug-drug interactions, ABCB1 polymorphisms and expression, and other sources of physiologic or metabolic variability.
(© 2023 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
References: AAPS J. 2016 Jan;18(1):228-38. (PMID: 26559435)
J Clin Pharmacol. 2021 Nov;61(11):1493-1504. (PMID: 34196005)
Pharmacol Ther. 1991 Oct;52(1):35-84. (PMID: 1687171)
Clin Pharmacol Ther. 1987 Jan;41(1):61-7. (PMID: 3802707)
Adv Enzyme Regul. 1997;37:321-33. (PMID: 9381978)
Mol Biol Cell. 1995 Sep;6(9):1215-29. (PMID: 8534917)
J Pharmacokinet Biopharm. 1991 Feb;19(1):1-20. (PMID: 2023106)
Biochem Biophys Res Commun. 1972 May 26;47(4):685-91. (PMID: 5026289)
Clin Pharmacokinet. 2019 Nov;58(11):1355-1371. (PMID: 31236775)
Arch Toxicol. 2007 Aug;81(8):553-63. (PMID: 17354009)
J Histochem Cytochem. 1990 Sep;38(9):1277-87. (PMID: 1974900)
Vet Comp Oncol. 2016 Jun;14(2):161-9. (PMID: 24502418)
J Natl Cancer Inst. 1996 Jul 17;88(14):994-9. (PMID: 8667431)
Cancer Res. 1977 Aug;37(8 Pt 1):2597-602. (PMID: 889590)
Med Pediatr Oncol. 1982;10(2):115-27. (PMID: 7070351)
Cancer Res. 1975 May;35(5):1116-20. (PMID: 1120303)
Cell. 1994 May 20;77(4):491-502. (PMID: 7910522)
J Med Chem. 2008 Jun 12;51(11):3275-87. (PMID: 18457386)
Cancer Res. 1965 Sep;25(8):1232-7. (PMID: 5839716)
J Vet Intern Med. 2010 May-Jun;24(3):579-86. (PMID: 20337920)
PLoS One. 2014 Aug 20;9(8):e105580. (PMID: 25141173)
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12. (PMID: 7310648)
Curr Drug Metab. 2008 May;9(4):310-22. (PMID: 18473749)
Drug Metab Pharmacokinet. 2005 Dec;20(6):452-77. (PMID: 16415531)
Ann N Y Acad Sci. 1975 Jun 30;253:27-50. (PMID: 50031)
Pharm Res. 1993 Jul;10(7):1093-5. (PMID: 8378254)
Proc Natl Acad Sci U S A. 1988 May;85(10):3580-4. (PMID: 3368466)
Toxicol Lett. 1988 Oct;43(1-3):117-37. (PMID: 3051521)
Pharmacogenetics. 2001 Nov;11(8):727-33. (PMID: 11692082)
J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):157-76. (PMID: 23315145)
Pharm Res. 2003 Oct;20(10):1607-11. (PMID: 14620515)
Annu Rev Pharmacol Toxicol. 1999;39:1-17. (PMID: 10331074)
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11725-30. (PMID: 15289602)
J Pharm Sci. 1971 Aug;60(8):1128-33. (PMID: 5127083)
Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. (PMID: 11770010)
Xenobiotica. 2008 Nov;38(11):1386-98. (PMID: 18988082)
Biochemistry. 1995 Jun 27;34(25):8050-60. (PMID: 7794918)
Eur J Clin Pharmacol. 1983;24(5):683-7. (PMID: 6873152)
CPT Pharmacometrics Syst Pharmacol. 2019 Oct;8(10):759-768. (PMID: 31420944)
Biochem Soc Trans. 1990 Apr;18(2):299-301. (PMID: 2379727)
Cancer Res. 1976 Apr;36(4):1499-502. (PMID: 1260766)
J Am Vet Med Assoc. 1988 Nov 1;193(9):1114-7. (PMID: 3058663)
Pharmaceutics. 2019 Apr 05;11(4):. (PMID: 30959827)
J Mol Biol. 1982 Jul 25;159(1):125-49. (PMID: 7131559)
Handb Clin Neurol. 2016;135:117-135. (PMID: 27432662)
Cancer Res. 1993 Nov 1;53(21):5121-6. (PMID: 8221648)
Cancer Res. 2008 Dec 1;68(23):9817-24. (PMID: 19047161)
Cancer Invest. 1999;17(7):479-85. (PMID: 10518192)
J Clin Invest. 2013 Oct;123(10):4131-3. (PMID: 24084745)
Cancer Chemother Pharmacol. 2021 Sep;88(3):451-464. (PMID: 34080039)
Cancer Res. 1976 Oct;36(10):3798-802. (PMID: 954003)
Leuk Res. 1993 Aug;17(8):663-8. (PMID: 8355510)
Eur J Nucl Med. 1983;8(1):19-22. (PMID: 6832184)
Biol Pharm Bull. 2006 Dec;29(12):2465-71. (PMID: 17142983)
Pharmacol Res Perspect. 2023 Feb;11(1):e01052. (PMID: 36631976)
J Pharm Sci. 2002 Jun;91(6):1488-501. (PMID: 12115848)
Clin Cancer Res. 2007 May 1;13(9):2768-76. (PMID: 17473210)
Pharmacol Ther. 1991;51(2):257-67. (PMID: 1784631)
Drug Metab Dispos. 2019 Mar;47(3):257-268. (PMID: 30567881)
J Pharm Sci. 2016 Feb;105(2):846-853. (PMID: 26202434)
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84. (PMID: 9249929)
Biochemistry. 1996 May 28;35(21):6806-14. (PMID: 8639632)
Clin Pharmacol Ther. 2013 Jul;94(1):80-94. (PMID: 23588303)
Drug Metab Dispos. 2015 Oct;43(10):1417-29. (PMID: 26180127)
J Pharm Sci. 1987 Dec;76(12):872-5. (PMID: 3440929)
معلومات مُعتمدة: K01 OD026526 United States OD NIH HHS; P30 CA046934 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: comparative oncology; physiologically-based pharmacokinetic modeling (PBPK); vinblastine
المشرفين على المادة: 5V9KLZ54CY (Vinblastine)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
0 (Antineoplastic Agents)
تواريخ الأحداث: Date Created: 20230112 Date Completed: 20230113 Latest Revision: 20231106
رمز التحديث: 20231106
مُعرف محوري في PubMed: PMC9834611
DOI: 10.1002/prp2.1052
PMID: 36631976
قاعدة البيانات: MEDLINE
الوصف
تدمد:2052-1707
DOI:10.1002/prp2.1052